Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ).
Adult
Algorithms
Cognitive Dysfunction
/ epidemiology
Comorbidity
Depressive Disorder, Major
/ epidemiology
Female
France
/ epidemiology
Humans
Machine Learning
Male
Medication Adherence
/ psychology
Neuropsychological Tests
Outpatients
/ psychology
Polypharmacy
Schizophrenia
/ classification
Schizophrenic Psychology
Young Adult
Clinical staging
Cognition
Comorbidity
Prognosis
Schizophrenia
Journal
Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617
Informations de publication
Date de publication:
08 06 2019
08 06 2019
Historique:
received:
17
10
2018
revised:
19
12
2018
accepted:
07
01
2019
pubmed:
15
1
2019
medline:
26
9
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Existing staging models have not been fully validated. Thus, after classifying patients with schizophrenia according to the staging model proposed by McGorry et al. (2010), we explored the validity of this staging model and its stability after one-year of follow-up. Using unsupervised machine-learning algorithm, we classified 770 outpatients into 5 clinical stages, the highest being the most severe. Analyses of (co)variance were performed to compare each stage in regard to socio-demographics factors, clinical characteristics, co-morbidities, ongoing treatment and neuropsychological profiles. The precision of clinical staging can be improved by sub-dividing intermediate stages (II and III). Clinical validators of class IV include the presence of concomitant major depressive episode (42.6% in stage IV versus 3.4% in stage IIa), more severe cognitive profile, lower adherence to medication and prescription of >3 psychotropic medications. Follow-up at one-year showed good stability of each stage. Clinical staging in schizophrenia could be improved by adding clinical elements such as mood symptoms and cognition to severity, relapses and global functioning. In terms of therapeutic strategies, attention needs to be paid on the factors associated with the more stages of schizophrenia such as treatment of comorbid depression, reduction of the number of concomitant psychotropic medications, improvement of treatment adherence, and prescription of cognitive remediation.
Identifiants
pubmed: 30639161
pii: S0278-5846(18)30808-X
doi: 10.1016/j.pnpbp.2019.01.003
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-234Investigateurs
Méja Andrianarisoa
(M)
Bruno Aouizerate
(B)
Fabrice Berna
(F)
Olivier Blanc
(O)
Lore Brunel
(L)
Ewa Bulzacka
(E)
Delphine Capdevielle
(D)
Isabelle Chéreau-Boudet
(I)
Gabrielle Chesnoy-Servanin
(G)
Jean-Marie Danion
(JM)
Thierry D'Amato
(T)
Arnaud Deloge
(A)
Claire Delorme
(C)
Hélène Denizot
(H)
Jean-Michel Dorey
(JM)
Caroline Dubertret
(C)
Julien Dubreucq
(J)
Catherine Faget
(C)
Cécile Fluttaz
(C)
Guillaume Fond
(G)
Sandrine Fonteneau
(S)
Franck Gabayet
(F)
Elisabeth Giraud-Baro
(E)
Marie-Christine Hardy-Baylé
(MC)
Delphine Lacelle
(D)
Christophe Lançon
(C)
Hakim Laouamri
(H)
Marion Leboyer
(M)
Tifenn Le Gloahec
(T)
Yann Le Strat
(Y)
Pierre-Michel Llorca
(PM)
Jasmina Mallet
(J)
Emeline Metairie
(E)
David Misdrahi
(D)
Christine Passerieux
(C)
Pauline Peri
(P)
Sylvie Pires
(S)
Céline Portalier
(C)
Romain Rey
(R)
Céline Roman
(C)
Mathilde Sebilleau
(M)
Aurélie Schandrin
(A)
Priscille Schneider
(P)
Franck Schurhoff
(F)
Arnaud Tessier
(A)
Anne-Marie Tronche
(AM)
Mathieu Urbach
(M)
Florence Vaillant
(F)
Aurélie Vehier
(A)
Pierre Vidailhet
(P)
Estelle Vilà
(E)
Hanan Yazbek
(H)
Anna Zinetti-Bertschy
(A)
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.